Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
MRK's Keytruda, driving over half of its pharma sales, remains in focus as Q1 nears, with growth expected from new indications and strong uptake.
Zacks·4d ago
More News
CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside
Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments.
Stocktwits·10d ago
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.
Zacks·13d ago
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.
Zacks·18d ago
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.
Zacks·19d ago
The Zacks Analyst Blog Roche Holding, AT&T and Amgen
AMGN, T, and Roche shares outperform as strong drug portfolios and wireless momentum offset key headwinds like pricing pressure and legacy declines.
Zacks·19d ago
Top Stock Reports for Roche, AT&T & Amgen
Roche's strong drug growth is offsetting legacy declines, while strategic deals aim to reshape its portfolio amid biosimilar pressure and FX headwinds.
Zacks·20d ago
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited options.
Zacks·20d ago
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
Zacks·25d ago
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.